Institut Jules Bordet
Belgium's only hospital devoted entirely to cancer, birthplace of the Breast International Group and a world centre for breast cancer trials.
The Institut Jules Bordet opened in 1939, named after the Nobel laureate immunologist Jules Bordet, and moved to a new building beside Erasme Hospital in Anderlecht in 2021 as part of the Hôpital Universitaire de Bruxelles. It is OECI-accredited as a comprehensive cancer centre. Martine Piccart co-founded the Breast International Group here and led the HERA trial of adjuvant trastuzumab; Christos Sotiriou's laboratory developed gene expression signatures for breast cancer and Michail Ignatiadis leads circulating tumour DNA studies, while Ahmad Awada's early-phase unit tests new agents. Bordet is also strong in haematology, nuclear medicine and surgical oncology, and Brussels hosts both BIG and EORTC headquarters.
- Breast International Group
- Breast cancer genomics and ctDNA
- Early-phase trials
- Haematology
- Nuclear medicine
Co-founded the Breast International Group and led HERA, the trial that made adjuvant trastuzumab standard.
Evandro de Azambuja is a breast oncologist who studies heart safety of HER2-targeted therapy in BIG trials.
Pages like this
not linked directly; found by shared links- InstitutionSOLTI Cancer Research Group
Shares Breast International Group (BIG), RNA sequencing & expression profiling, Trastuzumab, HER2-positive breast cancer.
- InstitutionIstituto Oncologico Veneto IRCCS
Shares Organisation of European Cancer Institutes, Trastuzumab, Monoclonal antibodies, HER2-positive breast cancer.
- InstitutionComprehensive Cancer Center Vienna – Medical University of Vienna / AKH
Shares Breast International Group (BIG), EORTC, Endocrine therapy (SERMs, AIs, SERDs), Diffuse large B-cell lymphoma.
- InstitutionGeorgetown Lombardi Comprehensive Cancer Center
Shares Endocrine therapy (SERMs, AIs, SERDs), Trastuzumab, Monoclonal antibodies, HER2-positive breast cancer.
- InstitutionBreast Cancer Trials
Shares Breast International Group (BIG), Endocrine therapy (SERMs, AIs, SERDs), Trastuzumab, HER2-positive breast cancer.
- IdeaWHO prequalification plus pooled demand to push biosimilar prices below 10% of the originator
Shares Trastuzumab, Monoclonal antibodies, HER2-positive breast cancer, Diffuse large B-cell lymphoma.
- InstitutionGEICAM Spanish Breast Cancer Group
Shares Breast International Group (BIG), Endocrine therapy (SERMs, AIs, SERDs), HER2-positive breast cancer, Triple-negative breast cancer (TNBC).
- InstitutionIstituto di Candiolo IRCCS – FPO
Shares Trastuzumab, Circulating tumour DNA (ctDNA), Monoclonal antibodies, HER2-positive breast cancer.